Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wallis

Showing results (321-330 of 332) with videos related to

Pageof 34
Sort By:
The Journal of Clinical Investigation|June 10, 2021
Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversionJason D Simmons, Phu T Van, Catherine M Stein, et al.
The European Respiratory Journal|June 10, 2010
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statementI Solovic, M Sester, J J Gomez-Reino, et al.
Trials|June 6, 2023
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosisA Dierig, M Hoelscher, S Schultz, et al.
Ebiomedicine|June 21, 2016
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 TrialDaniel F Hoft, Azra Blazevic, Asmir Selimovic, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|September 11, 2020
Post-tuberculosis lung health: perspectives from the First International SymposiumB W Allwood, M M van der Zalm, A F S Amaral, et al.
Frontiers in Immunology|June 19, 2026
A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of diseaseMehak Z Khan, Edward B Irvine, Deniz Cizmeci, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
The Lancet. Infectious Diseases|January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trialMartin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
Trials|February 26, 2026
panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbeD Mudzengi, S Mashatole, Q Xiang, et al.
Pageof 34

Showing results (321-330 of 332) with videos related to

Sort By:
Pageof 34
The Journal of Clinical Investigation|June 10, 2021
Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversionJason D Simmons, Phu T Van, Catherine M Stein, et al.
The European Respiratory Journal|June 10, 2010
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statementI Solovic, M Sester, J J Gomez-Reino, et al.
Trials|June 6, 2023
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosisA Dierig, M Hoelscher, S Schultz, et al.
Ebiomedicine|June 21, 2016
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 TrialDaniel F Hoft, Azra Blazevic, Asmir Selimovic, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|September 11, 2020
Post-tuberculosis lung health: perspectives from the First International SymposiumB W Allwood, M M van der Zalm, A F S Amaral, et al.
Frontiers in Immunology|June 19, 2026
A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of diseaseMehak Z Khan, Edward B Irvine, Deniz Cizmeci, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
The Lancet. Infectious Diseases|January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trialMartin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
Trials|February 26, 2026
panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbeD Mudzengi, S Mashatole, Q Xiang, et al.
Pageof 34